- Meta IMD™
- QUANTOSE™ IR
Metabolon Inc. offers the industry’s leading biochemical profiling platform. Metabolon’s patented platform provides a global analysis of complex biological samples for the discovery of markers and pathways associated with drug action and disease. This metabolomics-driven approach enables the identification of biomarkers useful for the development of a wide range of diagnostics and provides insight into complex biochemical processes, such as drug action, toxicology, and bioprocess optimization.
A member of the Weill Cornell Medicine faculty helped to develop the methodology that shaped Metabolon’s metabolomic experiments. The company's foundational technology is licensed from Cornell University.